Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma | AVESİS

Ankara University Research Information System

Amplitude of response, early mobilization (M) and pre-autologous transplant (ASCT) use of bortezomib (V) and/or thalidomide (T) are predictors of longer progression free (PFS) and/or overall survival (OS) in myeloma

Copy For Citation

BEKSAÇ M., Soydan E., ÖZKOCAMAN V., TOPÇUOĞLU P., Evranos B., Kizil M., ...More

49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 8 - 11 December 2007, vol.110, (Summary Text)

Publication Type: Conference Paper / Summary Text
Volume: 110
Doi Number: 10.1182/blood.v110.11.5096.5096
City: Georgia
Country: United States Of America
Ankara University Affiliated: Yes